0KBS.LSE Recordati
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 0.03%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2022.
Is 0KBS.LSE undervalued?
Graham numberThe Graham number of Recordati cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Recordati fundamental analysis
No fundamental analysis for Recordati yet.
Recordati stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Recordati
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular m…
Full company profileRecordati financial statements
Recordati annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 1.15B | 1.29B | 1.35B | 1.48B | 1.45B | - | - |
| Gross Profit | 793M | 905M | 957M | 1.04B | 1.04B | - | - |
| Operating Income | 327M | 406M | 442M | 465M | 469M | - | - |
| Net Income | 237M | 289M | 312M | 369M | 355M | - | - |
| Balance Sheet | |||||||
| Total Assets | 1.56B | 2.06B | 2.16B | 2.81B | 2.71B | - | - |
| Total Liabilities | 657M | 1.03B | 1.20B | 1.61B | 1.44B | - | - |
| Shareholders' Equity | 904M | 1.03B | 963M | 1.20B | 1.28B | - | - |
| Cash & Short-term Investments | 138M | 302M | 198M | 188M | 188M | - | - |
| Total Debt | 294M | 612M | 641M | 937M | 778M | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | 255M | 273M | 358M | 319M | 404M | 492M | - |
| Capital Expenditure | 19.7M | 14.6M | 19.4M | 22.1M | 21.3M | 21.9M | 23.9M |
| Ratios | |||||||
| ROE | 26.3% | 28.1% | 32.4% | 30.8% | 27.8% | - | - |
| ROA | 15.2% | 14.0% | 14.5% | 13.1% | 13.1% | - | - |
| Net Profit Margin | 20.6% | 22.4% | 23.1% | 24.9% | 24.5% | - | - |
| Debt to Equity | 0.32x | 0.60x | 0.66x | 0.78x | 0.61x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Recordati dividends
Recordati has not paid dividends in the last 9 fiscal years.
Who owns Recordati
- Insiders 46.82%
- Institutions 38.94%
- Public & others 14.24%
- Free float 102M
Recordati company profile
- Company name
- Recordati
- Ticker
- 0KBS.LSE
- ISIN
- IT0003828271
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 4,700
- Fiscal year end
- December
- Address
- Via Matteo Civitali,1, Milan, MI, Italy, 20148
- Phone
- 39 02 487871
- Website
- recordati.com
About Recordati
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing's syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.
Recordati management
10- Dr. Robert Koremans M.D.CEO & Director · born 1962
- Ms. Cathrin PettyExecutive Director · born 1973
- Mr. Giampiero MazzaExecutive Director · born 1969
- Mr. Michael McClellanChief Financial Officer · born 1971
- Ms. Eugenia Shen LitzVP & Head of Investor Relations
- Ms. Bibianne BonGroup Chief Legal Officer
- Ms. Laura ContiGroup Communications Director
- Mr. Gabriele FinziExecutive Vice President of Corporate Development, Licensing & Innovation
- Ms. Alessandra AbateGroup Chief People & Culture Officer
- Mr. Alberto MartinezExecutive Vice President of Specialty & Primary Care Business Unit